Sironax Overview
- Founded
-
2017

- Status
-
Private
- Employees
-
180

- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$200M
- Investors
-
22
Sironax General Information
Description
Developer of pharmaceuticals for inflammatory and neuro-degenerative diseases. The company researches apoptosis and other cell death pathways to develop quality pharmaceuticals, enabling healthcare professionals to prescribe advanced treatments to their patients.
Contact Information
Website
www.sironax.com.cn
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- Floor 8-10, Building 2, Medical Technology Center Phase II
- Zhongguancun Life Science Park, Changping District
- Beijing, 102206
- China
+86 010 0000 0000
Sironax Timeline
Sironax Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Early Stage VC (Series B) | 02-Aug-2022 | $200M | 00000 | Completed | Clinical Trials - General | |
2. Early Stage VC (Series A) | 30-Sep-2019 | 00000 | 00000 | Completed | Clinical Trials - General | |
1. Seed Round | 01-Jun-2018 | $15M | $15M | Completed | Startup |
Sironax Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Developer of pharmaceuticals for inflammatory and neuro-degenerative diseases. The company researches apoptosis and othe
Drug Discovery
Beijing, China
180
As of 2022
00000
00000000000
00000
Sironax Competitors (3)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Alector | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000 - 000 | 00000 |
000000000 00000000 | Formerly VC-backed | New York, NY | 00 | 000.00 | 00000000 | 000.00 |
000000 00000000000 | Corporation | Toronto, Canada | 0 | 000.00 | 000000000 | 000.00 |
Sironax Patents
Sironax Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2021275829-A1 | Azetidine cyclic ureas | Pending | 20-May-2020 | 0000000000 | |
CA-3183668-A1 | Azetidine cyclic ureas | Pending | 20-May-2020 | 0000000000 | |
CA-3183676-A1 | Piperazine cyclic ureas | Pending | 20-May-2020 | 0000000000 | |
CA-3183661-A1 | Receptor-interacting protein 1 inhibitors including piperazine heterocyclic amide ureas | Pending | 20-May-2020 | 0000000000 | |
CA-3174992-A1 | Ferroptosis inhibitors - diarylamine para-acetamides | Pending | 02-Mar-2020 | C07C259/06 |
Sironax Executive Team (4)
Sironax Board Members (1)
Name | Representing | Role | Since |
---|---|---|---|
Xiaodong Wang Ph.D | Sironax | Chairman & Co-Founder | 000 0000 |
Sironax Signals
Sironax Investors (22)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Abu Dhabi Investment Authority | Sovereign Wealth Fund | Minority | 000 0000 | 000000 0 | |
CBC Group | PE/Buyout | Minority | 000 0000 | 000000 0 | |
Future Innovation Fund | Venture Capital | Minority | 000 0000 | 000000 0 | |
Gaorong Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
Invus Opportunities | Venture Capital | Minority | 000 0000 | 000000 0 |